Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax + daunorubicin + cytarabine for newly diagnosed AML (Phase 2)
ChiCTR2600127203Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Composite complete remission rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600127203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127203.